Adam zhao

Adam zhao

Company: AnlongBio

Job title: Chief Executive Officer

Bio:

Dr. Zhao is the founder of AnlongBio/AnlongMed. Dr Zhao is among the first class graduated from Biological Science and Biotechnology department at Tsinghua University in 1990. He received his Ph.D in molecular biology from University of Pittsburgh School of Medicine and MBA from University of Chicago in the United States. Dr. Zhao was a senior manager at Pfizer in US. After returning to China in 2003, he founded Beijing LongMed Inc. and later became partner of CASH and C-Bridge Capital. Dr. Zhao has over 30 years of industry experience and excellent investment achievements, invested in Innovent, BerryGenomics, ASLETIS, I-Mab, Laekna, and GKHT. Dr. Zhao is the founding Chairman of Tsinghua Alumni Association for School of Life Sciences?School of Medicine and School of Pharmaceutical Sciences, a senior member of BayHelix group. AnlongMed is a leading venture fund in Chinese life sciences and Biotech, focusing on biotech & biopharma, medical devices, life sciences and medical services in China. Dr. Zhao also founded AnlongBio in 2019, a leading player in genetic medicine discovery in China, focusing on gene therapy, iRNA, mRNA, and other genetic medicines, with a leading product in gene therapy for ophthalmology already in clinical stages.

Seminars:

The Opportunities for Chinese Genetic Medicine 4:30 pm

Overview of Chinese genetic medicine development Current development on technology platforms and products AnlongBio's exploration on siRNA technologiesRead more

day: Day Two

A Hanson Wade Group Company

© Copyright 2025 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.